This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
“Culturally, we have been educated to assume that top leaders must know the best and the most, but inclusion is the opposite, it is making sure that we learn from others.”
For the fourth instalment of our Diversity, Equity & Inclusion Leadership series, the team recently explored D, E & I perspectives from the medtech industry with Guillaume Julien, VP HR Global Sales at Getinge, a leading global provider of medical products and systems, employing more than 10,000 people, with operations in 38 countries.
Coulter Partners was pleased to partner recently with Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, to secure the appointments of three new members to its Board of Directors.
A selection of C-suite, board, strategic commercial, R&D, medical and technical executive appointments for the past six months. Global hiring continues strongly and we look forward to collaborating on future projects!
Coulter Partners was pleased to partner recently with Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, to secure the appointment of Antonio Speziale as Chief Medical Officer.
Coulter Partners was pleased to partner recently with MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA (saRNA) therapeutics, to secure the appointments of Troels Koch, Senior Vice President, Chemistry and Ilian Tchakov, Vice President, Clinical Development.
A selection of recent successful placements and new projects globally. Focus in the 3rd quarter of 2021 has been predominantly: Immunology, Oncology, Rare Diseases, Infectious diseases, Neuro-degeneration, A.I. for drug discovery, DNA/ RNA, Vaccines, Drug delivery, Wound care, Telehealth, and Veterinary Services.
Coulter Partners announces the appointment of Dr Christelle Kerouedan as Marketing Director.
Christelle’s career has been dedicated to the Life Sciences and Technology sectors with experience gained in academia, start-ups, and communications agencies over the last 24 years. She combines strong marketing & communications expertise with hands-on entrepreneurial management experience, leadership and coaching skills, and a deeply rooted science understanding.
Coulter Partners was delighted to partner with Civetta Therapeutics, LLC, a biotechnology company focused on developing a pipeline of therapies that target beta-propeller proteins, to secure the appointment of Christopher D. Roberts, Ph.D., as Chief Executive Officer.
Dr. Roberts, who most recently served as Chief Scientific Officer of Black Diamond Therapeutics, brings more than 20 years of leadership experience discovering and developing novel therapies for oncology, immunology, virology and other indications.
“Good practice means that you have a diverse inclusive board and C-suite, not just token but systematic, and it needs to be beyond just gender and ethnicity. It's the different ways of thinking that matter.”
For the third instalment of our D&I Leadership series, the team recently had the privilege to spend some time with Dame Kate Bingham, Managing Partner at venture capital firm SV Health Investors, and former Chair of the Government's Vaccine Taskforce.
A selection of recent successful placements and new projects globally. Focus in the 2nd quarter of 2021 has been predominantly Gene Therapy, Oncology, Synthetic Biology, Cardiovascular, CNS Diseases, Respiratory Diseases, Animal Health, Drug Delivery, Rare Diseases, Digital Therapeutics, P.O.C. Diagnostics and Implantable Technologies.
Coulter Partners was very pleased to partner recently with Memo Therapeutics AG, an innovator in the field of antibody discovery and development, to secure the appointment of Dr. George Badita as Chief Medical Officer. “George brings his extensive expertise in Translational Medicine and Clinical Drug Development as the company is in a pivotal stage of growth and prepares to transition to a clinical-stage organization. I thank the Coulter Partners team for their outstanding professional support in securing George’s appointment,” commented CEO, Dr. Karsten Fischer.
The June HR Leadership Forum was focused on the topic of Diversity, Equity and Inclusion. Discussion revolved around these topics: 1) The Business Case – where are your organisations on the business case for D, E & I? How well is this understood by your organisation and do you see the link between diverse teams and better business performance?
2) The Inputs – what are you doing to improve diversity in the organisation? How do you select interventions that will work?
3) The Outputs – linked to the business case, what results, both tangible and intangible, are you seeing in the business because of a more diverse team?
Find out more...
Coulter Partners was very pleased to partner recently with 2N Pharma, a biotech company developing therapeutic drugs to treat neurological disorders, to secure the appointments of Alex Leech as Chair of the Board of Directors and John Kemp as Non-Executive Director. Coulter Partners and BioInnovation Institute have a Partnership Agreement to support BII Creation House companies as they build and develop their Boards and Executive teams.
“The business proof is in the outcome and the metrics should convince any doubters that diversity always wins”
For the second in this series of interviews, Coulter Partners recently talked about the importance of diversity, equity and inclusion in Life Sciences with Dr. Jason Mellad, CEO and Co-Founder of Start Codon, a Cambridge based accelerator. Dr. Mellad was previously CEO of Cambridge Epigenetix, a company pioneering the development and application of novel epigenetics-based diagnostics and therapeutics.
Coulter Partners recently partnered with the European Sperm Bank to bring more digital experience to their board. Fertility, life choices and women’s health are areas where Coulter Partners is now seeing a great deal more interest and investment. The CP team caught up with Jesper Funding Andersen – Chair of European Sperm Bank - to discuss this broad topic...
"To be innovative, competitive and disruptive, we need to be inclusive." In the first in a series of interviews with industry leaders about the importance of diversity, equity and inclusion in Life Sciences, Coulter Partners talks to Annalisa Jenkins, MBBS, FRCP. Dr. Jenkins serves as Chair and Independent Director on the boards of several Biopharma organisations and was previously President and CEO of Dimension Therapeutics.
Coulter Partners was delighted to partner again with Azitra Inc., to secure the appointment of Francisco Salva as President and Chief Executive Officer. Mr. Salva most recently served as President and Chief Executive Officer of Complexa, a clinical stage company developing innovative therapies for fibrotic and inflammatory diseases. Azitra is the first synthetic biology company focused on discovering and developing therapies to address serious skin conditions by harnessing the microbiome.
A selection of recent successful placements and new projects globally. Focus in the 1st quarter of 2021 has been mainly on AI/Digital, Animal Health, Synthetic Biology, Vaccines, Diagnostics, CNS Diseases, Infectious Diseases, Immuno-oncology, Rare Diseases, Ophthalmology, Regenerative Medicine and Contract Manufacturing.
Coulter Partners was very pleased to partner recently with OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, to secure the appointment of Dr Allison Jeynes as non-executive Chair of the Board of Directors.
A selection of C-suite, board, strategic commercial, R&D, medical and technical executive appointments for the past six months. Global hiring continues strongly and we look forward to collaborating on future projects!
At their first HR Leadership Forum of the year in January, Coulter Partners launched the HR & Talent Leadership Pulse. This survey is designed for senior HR and Talent leaders globally in Life Sciences, Healthcare and Digital Health. Please take part and help us build a comprehensive picture... Through 2020 we saw incredible transformations across organisations, with HR and Talent professionals leading the way. To support this community in 2021, Coulter Partners has created the pulse survey which will continue to run throughout the year and monitor developments. 
Coulter Partners was delighted to partner again recently with Optimapharm to secure the appointments of Walter Miller as Chief Finance Officer and Dr Charles Woler, M.D., Ph.D., as Non-Executive Director. Optimapharm is a contract research organization (CRO) managing clinical trials on behalf of leading biotech, pharma and medical devices companies in 27 countries across EMEA.
Global Life Sciences executive search specialist, Coulter Partners is delighted to announce continuing growth across the company in 2021. The London team expands with new Associates, Lucy Webb and Ana Delgado, Research Analysts, Jacob Taylor and Liam Fryer, and Director, Carina McEntire. In the US, Ayn Teigman is appointed Associate in New York and Irlanda Almendarez joins as Senior Research Associate in California. In Frankfurt, the team is strengthened with Sonia Keim, Associate and Katja Färber, Senior Research Associate.
Coulter Partners recently talked to Dr James Field, Chief Executive Officer and Founder of LabGenius about digital disruption and talent in drug discovery. He told us, "We’ve developed a protein engineering platform that tightly integrates synthetic biology, machine learning, robotic automation and next generation sequencing. To achieve this, we’ve built a 50-strong team of data scientists, software engineers, automation engineers, drug discovery experts, molecular biologists, synthetic biologists… the list goes on...Our greatest challenge is one of organisational engineering: how to structure diverse teams of scientists and engineers to create value at the confluence of so many disparate technologies."
New York, February 9, 2021 The Association of Executive Search and Leadership Consultants (AESC), the global standards-setting body for the executive search and leadership consulting profession, today announces 2021 officers and representatives to the AESC Council of Europe and Africa. Joe Coulter, newly announced AESC Europe and Africa Council Chair, commented: “The AESC Council of Europe and Africa plays an important role in ensuring AESC’s ongoing commitment to the highest standards in the executive search and leadership consulting profession across the region. I look forward to working with my fellow Council members to ensure we are creating the future of the profession on behalf of the clients we serve.” 
Coulter Partners kicked off 2021 with the first HR Leadership Forum of the year. The Forum was set up in 2020 to bring together the HR community to discuss key topics and share experiences among peers. Topics included changes in talent behaviour, onboarding and retention, collaboration models in hybrid environments, management expectations and normalisation trends. The next forum will gather on 24 February...
The Association of Executive Search and Leadership Consultants (AESC), the standards-setting body for the executive search and leadership consulting profession worldwide, today announces 2021 officers and the appointments of three new Directors to its Global Board. Coulter Partners is delighted to announce Joe’s appointment to the Board, together with his promotion to Chair of the AESC Council of Europe and Africa.
A selection of recent successful placements and new projects globally. Focus in the 4th quarter of 2020 has been mainly on Rare diseases, Artificial Intelligence, Dental, Vaccines, P.O.C. Diagnostics, Gene therapy, Oncology, Cardiovascular, Women's health, Neurology, Animal health and Venture teams.
After a year like no other we are charging into 2021 with hope and energy! Coulter Partners is indebted to the many people risking their own wellbeing on the front line to help those in need, and we are also completely awed by the dedication and energy of the scientists worldwide, whose unstinting work is enabling us all to look forward to a better future. A HUGE THANK YOU to everyone we have worked with in 2020, whose adaptability and perseverance have been so invaluable in helping us achieve our mutual goals. As vaccines begin to roll out, we are sure that together we can overcome the challenges ahead and help build a future we can be proud of.
Coulter Partners was delighted to partner with ObsEva SA (NASDAQ: OBSV / SIX: OBSN) to secure the appointment of Brian O’Callaghan as Chief Executive Officer and member of the company’s Executive Committee, effective 1 December 2020. He will succeed Dr Ernest Loumaye and be proposed for election on ObsEva’s Board of Directors at the next company AGM. ObsEva SA is a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health